Luís Felipe Arantes Moya

O histiocitoma é uma neoplasia cutânea benigna originária das células de Langerhans. O tumor tem prevalência elevada em animais jovens, e embora tenha elevado índice mitótico e rápido crescimento, raramente ocorre metástase. Costuma aparecer em região de cabeça como uma lesão solitária alopécica e eritematosa, podendo ser diagnosticado por meio de exame citológico e histopatológico. Em alguns casos sofrem regressão espontânea, semanas após seu aparecimento, e em razão disto, não são prescritos tratamentos cirúrgicos ou medicamentosos rotineiramente, porém podem ser indicados em casos de lesões persistentes ou recidivantes. O objetivo deste trabalho é relatar um caso de histiocitoma em canino, fêmea da raça Golden Retriever de 7 anos. Apresentou histórico de aparecimento de múltiplos nódulos em orelha direita há 1 ano. Foi realizada excisão cirúrgica e exame histopatológico do tecido, que revelou histiocitoma. Após dois meses o tumor retornou acometendo novamente orelha direita, pálpebra direita, lábio e região temporal. Pela extensão da lesão e caráter recidivante, foi indicada conchectomia. O paciente não apresentou recidiva ou metástases, demonstrando a importância do diagnóstico assertivo para instituir o tratamento adequado para cada caso, aumentando a sobrevida e qualidade de vida dos pacientes.

Cell-based therapy using mesenchymal stem cells (MSCs) shows promise for treating several diseases due to their anti-inflammatory and immunomodulatory properties. To enhance the therapeutic potential of MSCs, in vitro priming strategies have been explored. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, may influence MSC proliferation, differentiation, and immunomodulatory properties. This study evaluates the immunomodulatory potential of equine adipose tissue-derived MSCs (EqAT-MSCs) primed with a CBD-rich cannabis extract. EqAT-MSCs (P3) were primed with CBD concentrations of 5 µM and 7 µM for 24 h. Morphological analysis, MTT assay, β-galactosidase activity, apoptosis assays, and gene expression of interleukins IL-1β, IL-6, IL-10, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) were conducted. Additionally, cannabinoid receptor 1 (CB1) and 2 (CB2) expression were evaluated in naïve EqAT-MSCs (P2–P5). The naïve EqAT-MSCs expressed CB1 and CB2 receptors. Priming with 5 µM significantly increased the expression of IL-10, TNF-α, and IFN-γ, while 7 µM decreased IL-1β and IL-6 expression. No significant changes were observed in other cytokines, MTT, β-galactosidase activity, or apoptosis. These findings demonstrate that naïve EqAT-MSCs express CB1 and CB2 receptors and priming with the extract modulates the expression of pro- and anti-inflammatory cytokines, highlighting its potential immunomodulatory role in EqAT-MSC-based therapies.

Cell-based therapy using mesenchymal stem cells (MSCs) shows promise for treating several diseases due to their anti-inflammatory and immunomodulatory properties. To enhance the therapeutic potential of MSCs, several in vitro priming strategies have been explored. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has been shown to influence MSC proliferation, differentiation, and inflammatory response. This study evaluates the immunomodulatory potential of equine adipose tissue-derived MSCs (EqAT-MSCs) primed with a CBD-rich cannabis extract. EqAT-MSCs (P3) were primed with CBD concentrations of 5 µM and 7 µM for 24 hours. Morphological analysis, apoptosis assays, and gene expression of interleukins IL-1β, IL-6, IL-10, interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) were conducted. Additionally, cannabinoid receptor 1 (CB1) and 2 (CB2) expression were evaluated in naïve EqAT-MSCs (P2–P5). Naïve EqAT-MSCs expressed both CB1 and CB2 receptors. Priming with 5 µM significantly increased the expression of IL-10, TNF-α, and IFN-γ, while 7 µM decreased IL-1β and IL-6 expression. No significant changes were observed in other cytokines or in apoptosis assays. These findings demonstrate that naïve EqAT-MSCs express CB1 and CB2 receptors and priming with the extract modulates the expression of pro- and anti-inflammatory cytokines, highlighting its potential immunomodulatory role in EqAT-MSC-based therapies.